← The Wire
BIIBNasdaq
BIOGEN INC.
Biological Products, (No Diagnostic Substances) · DE · CIK 875045
Biogen discovers, develops, and delivers innovative therapies for serious and complex diseases, focusing on neurology, immunology, and rare diseases
$29.53B
Market cap
$216.63
Last close
+0.3%
1D
+8.5%
5D
1.3M
Volume
Price · last 39 sessions+15.7%
May 4L $187.21 · H $216.63Jun 29
214
Total filings
Jun 10, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 10, 20268-K/ACompany UpdateJun 10, 20268-KMaterial Agreement · Acquisition / DispositionMay 14, 2026SC 13D/ASC 13D/AMay 14, 202610-Q10-QApr 29, 20268-KResults of OperationsApr 29, 2026DEFA14ADEFA14AApr 28, 2026DEF 14ADEF 14AApr 28, 20268-KResults of OperationsApr 6, 2026SC 13DSC 13DApr 6, 20268-KMaterial Agreement · Company UpdateMar 31, 20268-KExecutive ChangeMar 11, 20268-KExecutive Change · Company UpdateFeb 11, 202610-K10-KFeb 6, 20268-KResults of OperationsFeb 6, 20268-KResults of OperationsJan 14, 202610-Q10-QOct 30, 20258-KResults of OperationsOct 30, 20258-KResults of OperationsOct 14, 20258-KResults of OperationsJul 31, 202510-Q10-QJul 31, 20258-KResults of OperationsJul 7, 20258-KShareholder VoteJun 23, 2025DEFA14ADEFA14AJun 2, 20258-KCompany UpdateMay 12, 202510-Q10-QMay 1, 20258-KResults of OperationsMay 1, 2025DEFA14ADEFA14AApr 28, 2025DEF 14ADEF 14AApr 28, 202510-K10-KFeb 12, 20258-KResults of OperationsFeb 12, 20258-KExecutive ChangeJan 15, 20258-KExecutive Change · Reg FD DisclosureOct 30, 202410-Q10-QOct 30, 20248-KResults of OperationsOct 30, 20248-KExecutive ChangeSep 12, 20248-KMaterial Agreement · Agreement TerminatedAug 14, 202410-Q10-QAug 1, 20248-KResults of OperationsAug 1, 20248-KBylaw Amendment · Shareholder VoteJun 25, 2024DEFA14ADEFA14AApr 26, 2024DEF 14ADEF 14AApr 26, 202410-Q10-QApr 24, 20248-KResults of OperationsApr 24, 202410-K10-KFeb 14, 20248-KResults of OperationsFeb 13, 20248-KBylaw AmendmentDec 12, 20238-KExecutive ChangeNov 8, 202310-Q10-QNov 8, 20238-KResults of OperationsNov 8, 20238-K/AShareholder VoteSep 28, 20238-KCompany UpdateSep 26, 20238-KMaterial Agreement · New Debt / ObligationSep 1, 2023SC 13DSC 13DAug 7, 2023DEFA14ADEFA14AJul 31, 20238-KMaterial Agreement · Bylaw AmendmentJul 31, 2023DEFA14ADEFA14AJul 28, 20238-KCompany UpdateJul 28, 202310-Q10-QJul 25, 20238-KResults of OperationsJul 25, 20238-KShareholder VoteJun 29, 2023DEFA14ADEFA14AJun 13, 2023DEFA14ADEFA14AJun 12, 20238-KCompany UpdateMay 3, 2023DEFA14ADEFA14AApr 28, 2023DEF 14ADEF 14AApr 28, 202310-Q10-QApr 25, 20238-KResults of OperationsApr 25, 20238-KBylaw AmendmentApr 18, 20238-KExecutive Change · Company UpdateMar 9, 202310-K10-KFeb 15, 20238-KResults of OperationsFeb 15, 20238-KExecutive Change · Reg FD DisclosureNov 10, 202210-Q10-QOct 25, 20228-KResults of OperationsOct 25, 202210-Q10-QJul 20, 20228-K/AResults of OperationsJul 20, 20228-KResults of OperationsJul 20, 20228-KExecutive Change · Shareholder VoteJun 21, 2022DEFA14ADEFA14AJun 7, 2022
Insider Activity
In the 90 days to Feb 12, 2026: 1 insider bought $585 · 1 sold $666K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 12, 2026 | Murphy NicoleHead of Pharm Ops and Tech | Buy | 3 | $195.04 | $585 |
| Feb 9, 2026 | Singhal PriyaHead of Development | Sell | 2,660 | $199.83 | $532K |
| Feb 2, 2026 | Singhal PriyaHead of Development | Sell | 748 | $179.30 | $134K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
Coverage (30d): 1 reputable article · skews ▼ negative.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance